Westlake Village-based biotech MannKind announced a distribution agreement with Australian Medical & Scientific Ltd. for its inhalable insulin product Afrezza May 16. The news sent its stock up more than 6 percent in after-hours trading, after it closed down 3.8 percent to $1.27. "We are excited to partner with AMSL Diabetes to accelerate patients’ access…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
